How Is Amgen’s Stock Performance Compared to Other General Drug Manufacturers

Thousand Oaks, California-based Amgen Inc. (AMGN) is a leading biotechnology company that discovers, develops, manufactures, and delivers innovative biologic medicines for serious diseases. With a market capitalization of approximately $233.8 billion, the company focuses on oncology, inflammation, general medicine, and rare diseases, leveraging human genetics and advanced biologics manufacturing to improve patient outcomes globally.

Companies worth $200 billion or more are generally described as “mega-cap stocks,” and AMGN fits that description, with its market cap exceeding this threshold and reflecting its substantial size, influence, and dominance within the general drug manufacturers industry. Amgen stands out for its strong portfolio of innovative therapies, including Repatha, Prolia, and Enbrel, alongside a growing oncology pipeline. Its exceptional profitability, product-sales growth, and international expansion demonstrate strong demand, operational efficiency, and potential for continued growth.

AMGN has slipped 3.3% from its 52-week high of $447.03, reached recently on August 25, 2026. Over the past three months, AMGN stock has climbed 28.5%, outperforming the Invesco Pharmaceuticals ETF (PJP), which has gained 15.2% over the same period.

Shares of AMGN have gained 32.1% year to date and 51.4% over the past 52 weeks, outperforming PJP’s 21.7% year-to-date gain and 40.2% return over the past year.

AMGN has traded above its 50-day and 200-day moving averages since late June, indicating a sustained uptrend.

On August 4, AMGN shares rose about 2.9% after reporting its Q2 results. Adjusted EPS of $6.29 surpassed Wall Street expectations of $5.60, while revenue of $10.05 billion beat forecasts of $9.44 billion. AMGN has outperformed the broader market, supported by robust revenue, strong free cash flow generation, and stellar returns on capital. These strengths give the company bargaining power, financial flexibility to invest in growth or return capital, and the ability to demonstrate effective capital allocation.

In the competitive General Drug Manufacturers industry, top rival Johnson & Johnson (JNJ) has underperformed AMGN, gaining 29.5% year-to-date. However, JNJ has shown resilience over the past 52 weeks, gaining 52.8% and outperforming AMGN.

Wall Street analysts are moderately bullish on AMGN’s prospects. The stock has a consensus “Moderate Buy” rating from the 35 analysts covering it, while its current share price trades above the mean price target of $397.87.